| scholarly article | Q13442814 |
| P2093 | author name string | Ping Zhao | |
| Long Yu | |||
| Qian Liu | |||
| Liang Peng | |||
| Zhuan Zhou | |||
| Hai Hu | |||
| Jian Pan | |||
| Li-Xin Sun | |||
| Li-Chao Sun | |||
| Zhi-Hua Yang | |||
| Yu-Liang Ran | |||
| Yue-Min Sun | |||
| P433 | issue | 10 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | cancer metastasis | Q120912394 |
| P304 | page(s) | 1660-1669 | |
| P577 | publication date | 2009-07-22 | |
| P1433 | published in | Carcinogenesis | Q326022 |
| P1476 | title | Secreted LOXL2 is a novel therapeutic target that promotes gastric cancer metastasis via the Src/FAK pathway | |
| P478 | volume | 30 |
| Q42317241 | A Phase II Randomized, Double-Blind, Placebo-Controlled Study of Simtuzumab or Placebo in Combination with Gemcitabine for the First-Line Treatment of Pancreatic Adenocarcinoma |
| Q40314116 | A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of Simtuzumab in Combination with FOLFIRI for the Second-Line Treatment of Metastatic KRAS Mutant Colorectal Adenocarcinoma |
| Q35980499 | A general protease digestion procedure for optimal protein sequence coverage and post-translational modifications analysis of recombinant glycoproteins: application to the characterization of human lysyl oxidase-like 2 glycosylation |
| Q38237959 | A new role for LOX and LOXL2 proteins in transcription regulation |
| Q39659310 | Allosteric inhibition of lysyl oxidase–like-2 impedes the development of a pathologic microenvironment |
| Q33820289 | An Impermeant Ganetespib Analog Inhibits Extracellular Hsp90-Mediated Cancer Cell Migration that Involves Lysyl Oxidase 2-like Protein |
| Q35268434 | An novel role of sphingosine kinase-1 (SPHK1) in the invasion and metastasis of esophageal carcinoma |
| Q38078237 | Biomarkers for predicting future metastasis of human gastrointestinal tumors. |
| Q55516060 | Clinical Implications of Lysyl Oxidase-Like Protein 2 Expression in Pancreatic Cancer. |
| Q55224859 | Clinical relevance of lysyl oxidase-like 2 and functional mechanisms in glioma. |
| Q33859309 | Detection of Lysyl Oxidase-Like 2 (LOXL2), a Biomarker of Metastasis from Breast Cancers Using Human Blood Samples. |
| Q61454345 | Divergent roles of lysyl oxidase family members in ornithine decarboxylase- and RAS-transformed mouse fibroblasts and human melanoma cells |
| Q54376072 | Down-regulation of lysyl oxidase-like 2 (LOXL2) is associated with disease progression in lung adenocarcinomas. |
| Q64118718 | Downregulation of lysyl oxidase and lysyl oxidase-like protein 2 suppressed the migration and invasion of trophoblasts by activating the TGF-β/collagen pathway in preeclampsia |
| Q37520614 | Emerging role of LOXL2 in the promotion of pancreas cancer metastasis |
| Q37472221 | Establishment of a gastric cancer subline with high metastatic potential using a novel microfluidic system |
| Q55276271 | Evaluation of Fluorine-18-Labeled α1(I)-N-Telopeptide Analogs as Substrate-Based Radiotracers for PET Imaging of Melanoma-Associated Lysyl Oxidase. |
| Q61805366 | Exosome-mediated secretion of LOXL4 promotes hepatocellular carcinoma cell invasion and metastasis |
| Q31121236 | Expression of ST3GAL4 leads to SLe(x) expression and induces c-Met activation and an invasive phenotype in gastric carcinoma cells |
| Q36672445 | Extracellular matrix remodeling: the common denominator in connective tissue diseases. Possibilities for evaluation and current understanding of the matrix as more than a passive architecture, but a key player in tissue failure |
| Q38177145 | Human copper-dependent amine oxidases. |
| Q38242121 | Human lysyl oxidase-like 2. |
| Q92214993 | Identification and characterization of the promoter of cancer-related gene LOXL2 |
| Q38951237 | Identification of a novel lysyl oxidase-like 2 alternative splicing isoform, LOXL2 Δe13, in esophageal squamous cell carcinoma |
| Q36283239 | Identification of significant pathways in gastric cancer based on protein-protein interaction networks and cluster analysis |
| Q64964306 | Identification of two molecular subtypes in canine mast cell tumours through gene expression profiling. |
| Q64936900 | Increased Expression of the Matrix-Modifying Enzyme Lysyl Oxidase-Like 2 in Aggressive Hepatocellular Carcinoma with Poor Prognosis. |
| Q51319814 | Increased lysyl oxidase-like 2 associates with a poor prognosis in non-small cell lung cancer. |
| Q34027580 | Increased secretory leukocyte protease inhibitor (SLPI) production by highly metastatic mouse breast cancer cells |
| Q26767150 | Influence of Immune Myeloid Cells on the Extracellular Matrix During Cancer Metastasis |
| Q92305732 | Interplay Between LOX Enzymes and Integrins in the Tumor Microenvironment |
| Q90642659 | LOXL2 Expression Status Is Correlated With Molecular Characterizations of Cervical Carcinoma and Associated With Poor Cancer Survival via Epithelial-Mesenchymal Transition (EMT) Phenotype |
| Q41957208 | LOXL2 catalytically inactive mutants mediate epithelial-to-mesenchymal transition. |
| Q39112374 | LOXL2 expression is associated with invasiveness and negatively influences survival in breast cancer patients. |
| Q34303455 | LOXL2 in epithelial cell plasticity and tumor progression |
| Q37690525 | LOXL2 induces aberrant acinar morphogenesis via ErbB2 signaling |
| Q37346579 | LOXL2-mediated matrix remodeling in metastasis and mammary gland involution |
| Q38723997 | Lysyl Oxidase Isoforms and Potential Therapeutic Opportunities for Fibrosis and Cancer |
| Q37631469 | Lysyl Oxidase and the Tumor Microenvironment |
| Q64114248 | Lysyl Oxidase-Like Protein 2 Promotes Tumor Lymphangiogenesis and Lymph Node Metastasis in Breast Cancer |
| Q46907178 | Lysyl Oxidase-like Protein LOXL2 Promotes Lung Metastasis of Breast Cancer |
| Q37299696 | Lysyl oxidase activity regulates oncogenic stress response and tumorigenesis. |
| Q55176262 | Lysyl oxidase family members in urological tumorigenesis and fibrosis. |
| Q38241992 | Lysyl oxidase in cancer research |
| Q38937873 | Lysyl oxidase isoforms in gastric cancer. |
| Q36284915 | Lysyl oxidase, extracellular matrix remodeling and cancer metastasis |
| Q50677852 | Lysyl oxidase-like 2 (LOXL2) and E47 EMT factor: novel partners in E-cadherin repression and early metastasis colonization. |
| Q24298337 | Lysyl oxidase-like 2 (LOXL2) controls tumor-associated cell proliferation through the interaction with MARCKSL1 |
| Q34197948 | Lysyl oxidase-like 2 (LOXL2), a new regulator of cell polarity required for metastatic dissemination of basal-like breast carcinomas |
| Q35527142 | Lysyl oxidase-like 2 represses Notch1 expression in the skin to promote squamous cell carcinoma progression. |
| Q54191996 | Lysyl oxidase-like 4 (LOXL4) promotes proliferation and metastasis of gastric cancer via FAK/Src pathway. |
| Q37233956 | MCF-7 cells expressing nuclear associated lysyl oxidase-like 2 (LOXL2) exhibit an epithelial-to-mesenchymal transition (EMT) phenotype and are highly invasive in vitro. |
| Q33912845 | MMP28 (epilysin) as a novel promoter of invasion and metastasis in gastric cancer |
| Q55318272 | Matrix stiffness-upregulated LOXL2 promotes fibronectin production, MMP9 and CXCL12 expression and BMDCs recruitment to assist pre-metastatic niche formation. |
| Q91999628 | Mechanism for oral tumor cell lysyl oxidase like-2 in cancer development: synergy with PDGF-AB |
| Q93354312 | MiR-192, miR-200c and miR-17 are fibroblast-mediated inhibitors of colorectal cancer invasion |
| Q38344322 | Modulation of lysyl oxidase-like 2 enzymatic activity by an allosteric antibody inhibitor |
| Q58029144 | Multiple Functions of Lysyl Oxidase Like-2 in Oral Fibroproliferative Processes |
| Q35622533 | Novel insights into the function and dynamics of extracellular matrix in liver fibrosis |
| Q38909572 | Orthotopic non-metastatic and metastatic oral cancer mouse models |
| Q39102336 | Overcoming a species-specificity barrier in development of an inhibitory antibody targeting a modulator of tumor stroma. |
| Q34162284 | Phosphorylation of focal adhesion kinase at Tyr397 in gastric carcinomas and its clinical significance |
| Q24309073 | Post-translational modifications of recombinant human lysyl oxidase-like 2 (rhLOXL2) secreted from Drosophila S2 cells |
| Q33688524 | Pre-clinical evaluation of small molecule LOXL2 inhibitors in breast cancer |
| Q99576557 | Promotive effect of Talin-1 protein on gastric cancer progression through PTK2-PXN-VCL-E-Cadherin-CAPN2-MAPK1 signaling axis |
| Q91803447 | Proteomic Profiling of Human Prostate Cancer-associated Fibroblasts (CAF) Reveals LOXL2-dependent Regulation of the Tumor Microenvironment |
| Q92997590 | ROS Generation and Antioxidant Defense Systems in Normal and Malignant Cells |
| Q38341297 | Receptor activity modifying protein‐3 mediates the protumorigenic activity of lysyl oxidase‐like protein‐2 |
| Q45393126 | Role of LOXL2 in the epithelial-mesenchymal transition and colorectal cancer metastasis |
| Q92630759 | SMYD3: An Oncogenic Driver Targeting Epigenetic Regulation and Signaling Pathways |
| Q90394579 | Serine arginine protein kinase 1 (SRPK1): a moonlighting protein with theranostic ability in cancer prevention |
| Q82341396 | Significant association of SRC protein expression with the progression, recurrence, and prognosis of oral squamous cell carcinoma in Taiwan |
| Q64095672 | Silencing of lysyl oxidase‑like 2 inhibits the migration, invasion and epithelial‑to‑mesenchymal transition of renal cell carcinoma cells through the Src/FAK signaling pathway |
| Q26798158 | Splicing Regulators and Their Roles in Cancer Biology and Therapy |
| Q47625476 | Src promotes EGF-induced epithelial-to-mesenchymal transition and migration in gastric cancer cells by upregulating ZEB1 and ZEB2 through AKT. |
| Q39146859 | Synergistic antitumor effects of dasatinib and oxaliplatin in gastric cancer cells |
| Q39460209 | Targets of the tumor suppressor miR-200 in regulation of the epithelial-mesenchymal transition in cancer. |
| Q38981265 | The 2016 John J. Abel Award Lecture: Targeting the Mechanical Microenvironment in Cancer |
| Q37190899 | The effect of LOXL2 in hepatocellular carcinoma |
| Q92015141 | The interaction of LOXL2 with GATA6 induces VEGFA expression and angiogenesis in cholangiocarcinoma |
| Q51701163 | The potential for LOXL2 as a target for future cancer treatment. |
| Q38027412 | The rationale for targeting the LOX family in cancer |
| Q39055609 | Therapeutical potential of deregulated lysine methyltransferase SMYD3 as a safe target for novel anticancer agents |
| Q35886637 | Toxicarioside A inhibits SGC-7901 proliferation, migration and invasion via NF-κB/bFGF signaling |
| Q36498118 | Tumor-suppressive microRNA-29 family inhibits cancer cell migration and invasion directly targeting LOXL2 in lung squamous cell carcinoma |
| Q38861461 | Tumour-suppressive microRNA-29s directly regulate LOXL2 expression and inhibit cancer cell migration and invasion in renal cell carcinoma |
| Q55154175 | Upregulation of bone morphogenetic protein 1 is associated with poor prognosis of late-stage gastric Cancer patients. |
| Q42118077 | ZEB1 induces LOXL2-mediated collagen stabilization and deposition in the extracellular matrix to drive lung cancer invasion and metastasis. |
Search more.